| Company Name: | St. Jude Medical, Incorporated | | Ticker Symbol: | STJ | | | WWW Address: | www.sjm.com | | CEO: | Daniel J. Starks | | No. of Employees: | 14,000 | | Common Issue Type: | CS | | Business Description: | The Company develops, manufactures and distributes cardiovascular medical devices for the cardiac rhythm management, cardiology & cardiac surgery & atrial fibrillation therapy areas and neurostimulation devices for the management of chronic pain.
|
| | | Industry Information: | HEALTH SERVICES - Medical Appliances & Equipment [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 34.32 |  -0.18 | 34.28 | 34.73 | 34.38 | 34.66 | 34.25 | 3613771 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 11,943.4 | 348.0 | 0.56 | 1.10 | 0.00 | 30.1 | 0.0 | 41.96 - 25.00 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 34.32 | $ | | PE Ratio - LTM | 30.1 | |
| Market Capitalisation | 11,942.7 | mil |
| Latest Shares Outstanding | 348.0 | mil |
| Earnings pS (EPS) | 1.10 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 311,661 | $ |
| Effective Tax Rate | 39.1 | % |
| Float | 341.0 | mil |
| Float as % of Shares Outstanding | 98.0 | % |
| Foreign Sales | 2,044 | mil |
| Domestic Sales | 2,320 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 37.50 | % |
| Research & Devlopment (R&D) as % of Revenue | 12.20 | % |
| Gross Profit Margin | 77.3 | % |
| EBITDA Margin | 27.6 | % |
| Pre-Tax Profit Margin | 13.0 | % |
| Assets Turnover | 0.7 | % |
| Return on Assets (ROA) | 5.7 | % |
| Return on Equity (ROE) | 11.0 | % |
| Return on Capital Invested (ROCI) | 7.5 | % |
| Current Ratio | 2.5 | |
| Leverage Ratio (Assets/Equity) | 1.9 | |
| Interest Cover | 18.3 | |
| Total Debt/Equity (Gearing Ratio) | 0.55 | |
| LT Debt/Total Capital | 31.0 | % |
| Working Capital pS | 5.17 | $ |
| Cash pS | 2.29 | $ |
| Book-Value pS | 10.31 | $ |
| Tangible Book-Value pS | 3.15 | $ |
| Cash Flow pS | 1.72 | $ |
| Free Cash Flow pS | 0.23 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 3.33 | |
| Price/Tangible Book Ratio | 10.88 | |
| Price/Cash Flow | 19.9 | |
| Price/Free Cash Flow | 151.0 | |
| P/E as % of Industry Group | 106.0 | % |
| P/E as % of Sector Segment | 15.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | Cash Payment |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.4 | 101 | 32,282 | 149,484 |
| 4 Weeks | 35.64 | 33.92 | 34.40 | -0.2 | 99 | 37,494 | 749,881 |
| 13 Weeks | 40.04 | 31.66 | 37.79 | -9.2 | 85 | 50,103 | 3,206,585 |
| 26 Weeks | 41.96 | 31.66 | 36.72 | -6.5 | 76 | 44,146 | 5,606,574 |
| 52 Weeks | 41.96 | 25.00 | 27.64 | 24.2 | 91 | 41,116 | 10,320,106 |
| YTD | 41.96 | 28.86 | - | 4.1 | 86 | 41,897 | 9,426,787 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 34.60 | 34.80 | 35.72 | 37.36 | 36.90 | 0.56 | 0.55 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 14.87 | 97.3 | 11.50 |
| Income | 2.18 | 5.3 | -6.59 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 9.67 | NA | -22.49 |
| R&D | 15.07 | NA | 10.43 |
| Normalized Inc. | 12.50 | NA | 12.97 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 7.7 | 7.0 | 15.5 |
| Earnings % | 1.5 | -13.5 | -31.3 |
| EPS % | 2.4 | -12.7 | -30.8 |
| EPS $ | 0.04 | -0.07 | -0.49 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 18.38 |
| Current Ratio | 2.0 |
| Quick Ratio (Acid Test) | 1.2 |
| Liquidity Ratio (Cash) | 0.13 |
| Receivables Turnover | 4.1 |
| Average Collection Period | 88 |
| Working Capital/Equity | 32.5 |
| Working Capital pS | 3.05 |
| Cash-Flow pS | 1.70 |
| Free Cash-Flow pS | 0.32 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 4.37 |
| Financial Leverage Ratio (Assets/Equity) | 1.8 |
| Debt Ratio | 43.5 |
| Total Debt/Equity (Gearing Ratio) | 0.37 |
| LT Debt/Equity | 0.35 |
| LT Debt/Capital Invested | 33.4 |
| LT Debt/Total Liabilities | 45.3 |
| Interest Cover | 28.9 |
| Interest/Capital Invested | 0.48 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 8.16 |
| Tobin's Q Ratio | 2.09 |
| Current P/E Ratio - LTM | 30.10 |
| Enterprise Value (EV)/EBITDA | 11.65 |
| Enterprise Value (EV)/Free Cash Flow | 144.82 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 10.88 |
| Price/Book Ratio - LTM | 3.33 |
| Price/Cash Flow Ratio | 19.9 |
| Price/Free Cash Flow Ratio - LTM | 151.0 |
| Price/Sales Ratio | 2.59 |
| P/E Ratio (1 month ago) - LTM | 29.1 |
| P/E Ratio (26 weeks ago) - LTM | 31.7 |
| P/E Ratio (52 weeks ago) - LTM | 13.8 |
| 5-Y High P/E Ratio | 50.8 |
| 5-Y Low P/E Ratio | 21.2 |
| 5-Y Average P/E Ratio | 33.4 |
| Current P/E Ratio as % of 5-Y Average P/E | 90 |
| P/E as % of Industry Group | 106.0 |
| P/E as % of Sector Segment | 15.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 14.7 |
| PER SHARE FIGURES |
| LT Debt pS | 3.26 |
| Current Liabilities pS | 2.98 |
| Tangible Book Value pS - LTM | 3.15 |
| Book Value pS - LTM | 10.31 |
| Capital Invested pS | 12.54 |
| Cash pS - LTM | 2.29 |
| Cash Flow pS - LTM | 1.72 |
| Free Cash Flow pS - LTM | 0.23 |
| Earnings pS (EPS) | 1.10 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 2.56 |
| Free Cash Flow Margin 5YEAR AVG | -0.47 |
| Net Profit Margin | 8.8 |
| Net Profit Margin - 5YEAR AVRG. | 13.8 |
| Equity Productivity | 1.35 |
| Return on Equity (ROE) | 11.9 |
| Return on Equity (ROE) - 5YEAR AVRG. | 16.0 |
| Capital Invested Productivity | 1.00 |
| Return on Capital Invested (ROCI) | 8.8 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 13.6 |
| Assets Productivity | 0.80 |
| Return on Assets (ROA) | 6.7 |
| Return on Assets (ROA) - 5YEAR AVRG. | 9.6 |
| Gross Profit Margin | 77.3 |
| Gross Profit Margin - 5YEAR AVRG. | 77.1 |
| EBITDA Margin - LTM | 27.6 |
| EBIT Margin - LTM | 13.8 |
| Pre-Tax Profit Margin | 14.5 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 19.5 |
| Effective Tax Rate | 39.1 |
| Effective Tax Rate - 5YEAR AVRG. | 29.6 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 278 |
| Revenue per Employee | 311,661 |
| Net Income per Employee | 27,452 |
| Average Collection Period | 91 |
| Receivables Turnover | 4.1 |
| Day's Inventory Turnover Ratio | 187 |
| Inventory Turnover | 1.9 |
| Inventory/Sales | 12.5 |
| Accounts Payble/Sales | 5.46 |
| Assets/Revenue | 1.25 |
| Net Working Capital Turnover | 4.15 |
| Fixed Assets Turnover | 1.20 |
| Total Assets Turnover | 0.8 |
| Revenue per $ Cash | 31.98 |
| Revenue per $ Plant | 4.45 |
| Revenue per $ Common Equity | 1.35 |
| Revenue per $ Capital Invested | 1.00 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 37.5 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 35.7 |
| Research & Devlopment (R&D) as % of Revenue | 12.2 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 12.2 |
|
|  
| | |  |  | |
| |